Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 257Carcinoma, Non-Small-Cell Lung 213Ovarian Neoplasms 134Lung Neoplasms 107Esophageal Neoplasms 69Triple Negative Breast Neoplasms 64Stomach Neoplasms 58Fallopian Tube Neoplasms 56Squamous Cell Carcinoma of Head and Neck 52Neoplasm Metastasis 50Head and Neck Neoplasms 44Esophageal Squamous Cell Carcinoma 43Carcinoma, Ovarian Epithelial 42Neoplasms 36Endometrial Neoplasms 34Uterine Cervical Neoplasms 32Recurrence 29Adenocarcinoma Of Esophagus 24Adenocarcinoma of Lung 22Urinary Bladder Neoplasms 21Melanoma 20Carcinoma, Squamous Cell 19Carcinoma 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 15Breast Neoplasms, Male 15Adenocarcinoma, Bronchiolo-Alveolar 13Peritoneal Neoplasms 12Inflammatory Breast Neoplasms 12Testicular Neoplasms 10

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal Squamous Cell Carcinoma × Paclitaxel × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡